Skip to main content

Russia, Belarus & Kazakhstan

  • 707 Accesses

Part of the AAPS Advances in the Pharmaceutical Sciences Series book series (AAPS,volume 28)


The Customs Union of Belarus, Kazakhstan and Russia is a form of trade and economic integration of Belarus, Kazakhstan and Russia which provides a unified customs territory within the mutual trade in goods and does not apply customs duties and economic restrictions, except for special protective, antidumping and countervailing measures. The Republics of Belarus and Kazakhstan and the Russian Federation, in accordance with the Agreement of October 6, 2007, established the Commission of the Customs Union, a single permanent regulatory agency of the Customs Union. At present the Commission of the Customs Union is expected to sign the Agreement on common principles of the circulation of goods and services (which includes drug products). In connection with this Agreement which contains an approach to prepare a unified guidance for BE studies, a plan for document preparation has been approved (a Custom Union BE guidance was approved in May 2017).


  • Active pharmaceutical ingredient (API)
  • Acceptance criteria
  • Area under the curve (AUC)
  • Bioavailability (BA)
  • Bioequivalence (BE)
  • Cmax
  • Confidence interval (CI)
  • Elimination rate constant
  • Essentially similar
  • European medicines agency (EMA)
  • Extravascular
  • Fixed-dose combination (FDC)
  • US food and drug administration (FDA)
  • Guidelines
  • Guidances
  • Multisource (generic) pharmaceutical product
  • Mutual recognition procedure (MRP)
  • Pharmaceutical alternatives
  • Pharmacodynamic
  • Pharmacokinetic
  • Dosage form
  • Pharmaceutical equivalence (PE)
  • Proportionally similar dosage forms
  • Regulations
  • Therapeutic equivalence (TE)
  • Tmax
  • Topical
  • Vasoconstrictor assay (VCA)

This is a preview of subscription content, access via your institution.


  1. Ramenskaya GV, Shokhin IE. Modern approaches to quality evaluation of generic drug products for their registration (a review). Pharm Chem J. 2010;43(9):512–5.

    CrossRef  Google Scholar 

  2. Davydova KS, Shokhin IE, Ramenskaya GV, Kukes VG. Interchangeability evaluation for generic drug products. Remedium. 2010;7:36–8.

    Google Scholar 

  3. Strategy of Development of the pharmaceutical industry in the Russian Federation for the period until 2020 (Pharma-2020 Strategy) official documents. – M.., 2009 г. (accessed date 02.05.2014).

  4. Federal Law of April 12, 2010 N 61-FZ “Circulation of Medicines” 2010.

    Google Scholar 

  5. URL: (accessed date 02.05.2014).

    Google Scholar 

  6. Methodical instructions for BE studies. – M., 2001.

    Google Scholar 

  7. Methodical instructions for BE studies. – M., 2004.

    Google Scholar 

  8. Methodical instructions for BE studies. – M., 2008.

    Google Scholar 

  9. Guidelines for the Expertise of Drugs. Vol. I. – M.: Grif&K, 2013. – 328 p.

    Google Scholar 

  10. National Standard GOST R 52379–2005 “Good Clinical Practice”.

    Google Scholar 

  11. Guideline on the investigation of BE. CPMP/EWP/QWP/1401/98 Rev. 1/ Corr. – EMA, 2010.

    Google Scholar 

  12. Guideline on bioanalytical method validation. EMEA/CHMP/EWP/192217/2009 – EMA, 2011.

    Google Scholar 

  13. Godovalnikov GV, Voronov GG. Instruction for registration requirements and rules for equivalence studies for generic drug products. Approved by Ministry of Healthcare of the Republic of Belarus 30.05.01, Reg No 73–0501. – Minsk, 2001. 25 p.

    Google Scholar 

  14. State Pharmacopoeia for the Republic of Belarus, IInd edition. Vol. 1. Registration requirements and rules for BE studies for generic drug products. / Ministry of Healthcare of the Republic of Belarus; edited by. A.A. Sheriakov. – Molodechno, Pobeda, 2012. p. 1092–130.

    Google Scholar 

  15. CPMP/EWP/QWP/1401/98Rev.1 Guidance on the Investigation of Bioequivalence. – London, 2010. p. 1–27.

    Google Scholar 

  16. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability/WHO Technical Report Series, No. 937, 2006. p. 347–90.

    Google Scholar 

  17. Moore JW, Flanner HH. Mathematical comparison of curves with an emphasis on in vitro dissolution profiles. Pharm Technol. 1996;20(6):64–74.

    Google Scholar 

  18. Coasta P, Sousa LJM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123–33.

    CrossRef  Google Scholar 

  19. Code of Health and the health care system of the Republic of Kazakhstan. 2009.

    Google Scholar 

  20. Order of the Ministry of Health № 744, (The rules of clinical researches and (or) pharmacological and medicinal drugs, medical products and medical equipment), 2009.

    Google Scholar 

  21. Order of the Ministry of Health № 442, (Approving the rules of preclinical researches, medico-biological experiments and clinical studies in the Republic of Kazakhstan), 2007.

    Google Scholar 

  22. Guideline “Conducting of good BE studies for drug products in the Republic of Kazakhstan” 2007.

    Google Scholar 

  23. Guidance for Bioequivalence Studies of Generic Drug Products on the Territory of the Eurasian Economic Union 2015.Правила БЭИ итог 20.02.2015 на сайт.pdf.

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to I. E. Shohin .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2017 American Association of Pharmaceutical Scientists

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Shohin, I.E., Rozhdestvenskiy, D.A., Medvedev, V.Y., Komarov, T.N., Grebenkin, D.Y. (2017). Russia, Belarus & Kazakhstan. In: Kanfer, I. (eds) Bioequivalence Requirements in Various Global Jurisdictions. AAPS Advances in the Pharmaceutical Sciences Series, vol 28. Springer, Cham.

Download citation